Literature DB >> 24357541

Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States.

Neil M Bressler1, Rohit Varma2, Quan V Doan3, Michelle Gleeson3, Mark Danese3, Julie K Bower4, Elizabeth Selvin4, Chantal Dolan5, Jennifer Fine5, Shoshana Colman5, Adam Turpcu5.   

Abstract

IMPORTANCE: Thickening of the center of the retina, diabetic macular edema (DME), is the most common cause of visual loss due to diabetes mellitus. Treatment of DME has improved dramatically, and the prompt diagnosis of DME and referral of these patients have become more critical. Nonetheless, awareness of and care for DME in the US population is uncharacterized.
OBJECTIVE: To characterize eye care and awareness of eye disease among persons with DME in the general US population. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of data from participants in the 2005 to 2008 National Health and Nutrition Examination Survey 40 years or older with diabetes mellitus and fundus photographs. MAIN OUTCOMES AND MEASURES: Among persons with DME, (1) awareness that diabetes has affected their eyes; (2) report on the last time they visited a diabetes specialist; (3) report on their last eye examination with pupil dilation; and (4) prevalence of visual impairment.
RESULTS: In 2010, only 44.7% (95% CI, 27.0%-62.4%) of US adults 40 years or older with DME reported being told by a physician that diabetes had affected their eyes or that they had retinopathy; 46.7% (95% CI, 27.5%-66.0%), that they had visited a diabetes nurse educator, dietician, or nutritionist for their diabetes mellitus more than 1 year ago or never; and 59.7% (95% CI, 43.5%-75.9%), that they had received an eye examination with pupil dilation in the last year. Among persons with DME, 28.7% (95% CI, 12.7%-44.7%) were visually impaired (defined as visual acuity worse than 20/40 in the eye with DME) based on visual acuity at the initial examination and 16.0% (95% CI, 2.5%-29.4%) based on best-corrected visual acuity. CONCLUSIONS AND RELEVANCE: Many persons with diabetes mellitus in the United States are not getting care that can prevent visual impairment and blindness. Strategies to increase awareness are warranted, especially given the recent availability of improved therapies for DME.

Entities:  

Mesh:

Year:  2014        PMID: 24357541      PMCID: PMC4576971          DOI: 10.1001/jamaophthalmol.2013.6426

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  12 in total

1.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

Authors:  Diana V Do; Quan Dong Nguyen; David Boyer; Ursula Schmidt-Erfurth; David M Brown; Robert Vitti; Alyson J Berliner; Bo Gao; Oliver Zeitz; Rene Ruckert; Thomas Schmelter; Rupert Sandbrink; Jeff S Heier
Journal:  Ophthalmology       Date:  2012-04-24       Impact factor: 12.079

2.  The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Ronald Klein; Kristine E Lee; Ronald E Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2009-10-31       Impact factor: 12.079

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  How effective are treatments for diabetic retinopathy?

Authors:  F L Ferris
Journal:  JAMA       Date:  1993-03-10       Impact factor: 56.272

5.  Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

Authors:  Michael J Elman; Haijing Qin; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Frederick L Ferris; Adam R Glassman; Raj K Maturi; Michele Melia
Journal:  Ophthalmology       Date:  2012-09-19       Impact factor: 12.079

6.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Authors:  Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E Lang; Pascale Massin; Reinier O Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

7.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

8.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

Authors:  Ranjan Rajendram; Samantha Fraser-Bell; Andrew Kaines; Michel Michaelides; Robin D Hamilton; Simona Degli Esposti; Tunde Peto; Catherine Egan; Catey Bunce; Richard David Leslie; Philip G Hykin
Journal:  Arch Ophthalmol       Date:  2012-08

9.  Causes and prevalence of visual impairment among adults in the United States.

Authors:  Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell
Journal:  Arch Ophthalmol       Date:  2004-04

10.  The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States.

Authors:  Monique S Roy; Ronald Klein; Benita J O'Colmain; Barbara E K Klein; Scot E Moss; John H Kempen
Journal:  Arch Ophthalmol       Date:  2004-04
View more
  23 in total

Review 1.  Dopamine metabolite levels in the vitreous of diabetic and non-diabetic humans.

Authors:  Andrew Hendrick; Jesse Smith; Chris Stelton; Scott Barb; Jiong Yan; Blaine Cribbs; Nieraj Jain; Steve Yeh; G Baker Hubbard; Li He; Susov Dhakal; P Michael Iuvone
Journal:  Exp Eye Res       Date:  2020-04-29       Impact factor: 3.467

2.  Comparison Among Methods of Retinopathy Assessment (CAMRA) Study: Smartphone, Nonmydriatic, and Mydriatic Photography.

Authors:  Martha E Ryan; Ramachandran Rajalakshmi; Vijayaraghavan Prathiba; Ranjit Mohan Anjana; Harish Ranjani; K M Venkat Narayan; Timothy W Olsen; Viswanathan Mohan; Laura A Ward; Michael J Lynn; Andrew M Hendrick
Journal:  Ophthalmology       Date:  2015-07-16       Impact factor: 12.079

3.  Does Identification of Previously Undiagnosed Conditions Change Care-Seeking Behavior?

Authors:  Rebecca M Myerson; Lisandro D Colantonio; Monika M Safford; Elbert S Huang
Journal:  Health Serv Res       Date:  2017-01-10       Impact factor: 3.402

Review 4.  Clinical Components of Telemedicine Programs for Diabetic Retinopathy.

Authors:  Mark B Horton; Paolo S Silva; Jerry D Cavallerano; Lloyd Paul Aiello
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

Review 5.  Cost-effectiveness of Different Diabetic Retinopathy Screening Modalities.

Authors:  Francisco J Pasquel; Andrew M Hendrick; Martha Ryan; Emily Cason; Mohammed K Ali; K M Venkat Narayan
Journal:  J Diabetes Sci Technol       Date:  2015-12-29

Review 6.  Current Challenges in Diabetic Retinopathy: Are We Really Doing Better?

Authors:  Jae Hyuck Lee; Su Jeong Song
Journal:  Endocrinol Metab (Seoul)       Date:  2016-06-10

Review 7.  Current and Next Generation Portable Screening Devices for Diabetic Retinopathy.

Authors:  J Morgan Micheletti; Andrew M Hendrick; Farah N Khan; David C Ziemer; Francisco J Pasquel
Journal:  J Diabetes Sci Technol       Date:  2016-02-16

8.  Revolution to a new standard treatment of diabetic macular edema.

Authors:  Lee M Jampol; Neil M Bressler; Adam R Glassman
Journal:  JAMA       Date:  2014-06-11       Impact factor: 56.272

9.  Longitudinal Commercial Claims-Based Cost Analysis of Diabetic Retinopathy Screening Patterns.

Authors:  Kathryn Fitch; Thomas Weisman; Tyler Engel; Adam Turpcu; Helen Blumen; Yamina Rajput; Purav Dave
Journal:  Am Health Drug Benefits       Date:  2015-09

10.  Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Authors:  Carl W Baker; Adam R Glassman; Wesley T Beaulieu; Andrew N Antoszyk; David J Browning; Kakarla V Chalam; Sandeep Grover; Lee M Jampol; Chirag D Jhaveri; Michele Melia; Cynthia R Stockdale; Daniel F Martin; Jennifer K Sun
Journal:  JAMA       Date:  2019-05-21       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.